2020 Biotech Portfolio Soars 55%, We’re Amazed. Next Up: The Coming Gold Rush.
1. Yep, We Are Absolutely Amazed At The Biotech Stock Review's 2020 Watch List Performance – Especially In The Light Of...
SEC Charges Microcap Fraud Scheme Participants Attempting to Capitalize on the COVID-19 Pandemic.
FOR IMMEDIATE RELEASE2020-131
Washington D.C., June 11, 2020 —
The Securities and...
Shark Tanks’ Kevin Harrington Gets Into Sanitizer Business.
Aphex BioCleanse Systems Welcomes Original Shark Tank Investor Kevin Harrington and World-Renowned Entrepreneur Mark Timm as Advisors
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.
Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.
Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in...
American Chemical Society
May 2020.
Higher rates of serious illness and death from coronavirus SARS-CoV-2...
Telehealth DTC Startup Ro is now Offering Coronavirus Assessments (ModernRetail).
Ro — a DTC telehealth company for everything from erectile dysfunction to helping quit smoking — has a new service aimed at...
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
